Document:

Exhibit 10.1

 

CONSULTING
AGREEMENT

 

This
Consulting Agreement (this "Agreement") is made as the 14 day of Sept. 2007 by and among Viral Genetics, Inc., a Delaware
corporation (the "Company"); and Anthony Freda Jr. (the "Consultant").

 

WHEREAS,
Consultant desire to render consulting services to the Company and the Company desires to retain Consultant for the purpose of
rendering such services, pursuant to the terms and conditions of this Agreement.

 

NOW,
THEREFORE, in consideration of the foregoing recitals and the mutual agreements and covenants contained herein, and for other
good and valuable consideration, the receipt and adequacy of which are hereby acknowledged, the parties hereto hereby agree as
follows:

 

SECTION 1

APPOINTMENT; TERM

 

Section
1.1. Appointment The Company hereby appoints Consultant, and Consultant hereby accepts such appointment, to serve as
Consultant to the Company and to perform such services described herein or as may be requested from time to time by the
Company and agreed to in writing by Consultant during the Term, as hereinafter defined, pursuant to the terms and conditions
of this Agreement. Consultant shall have no minimum time commitment but shall devote a reasonable and sufficient amount of
time to deliver services.

 

Section
1.2. Term. The term of this Agreement shall commence on the date hereof and expire on the six month anniversary date of
this Agreement, or on the earliest date this Agreement is terminated pursuant to Section 1.3 (the "Term").

 

Section
1.3Termination and/or Expiration. This Agreement may be terminated for cause or no cause as follows:

 

		(a)	at any time by the Company upon thirty (30) days written notice to Consultant, provided, that
                                                                 in the event the Company terminates this Agreement for any reason, the Company shall be responsible for all fees
                                                                 payable to Consultant pursuant to Section 3 and all other sections of this Agreement; and

 

		(b)	at any time after the 3-month anniversary of the date hereof, Consultant may terminate this
                                                                 Agreement at will, upon thirty (30) days written notice to the Company.

 

Section
1.4The Company and the Consultant are equally open to additional compensation agreements within an allotted amount of
time after discussions from both parties for future services rendered by the Consultant.

 

    	1

    	 

    

 

SECTION 2

DUTIES AND OBLIGATIONS OF
CONSULTANT

 

Section
2.1 General Duties. Consultant shall provide general business consulting services including, but not limited to, issues
related to: advising the Company regarding the development of the Company's human and outer• resources; advising on short-
and long-term marketing opportunities from time to time during the Term; and introducing the Company to third parties who may
be able to provide assistance to the Company as determined solely by the Company; all at such times as are mutually agreeable
to the Company and Consultant (the "Services"). Consultant shall perform such Services at their discretion.

 

Section
2.2 Other Activities. Consultant may engage in any other activities related to any industry including, but not limited
to, any industry that is competitive with the Company or any other industry during and alley the Term of this Agreement.

 

SECTION 3

COMPENSATION
OF CONSULTANT

 

Section
3.1Payment. As consideration for the Services, the Company shall pay to Consultant:

 

(a)           
four hundred thousand (400,000) shares (the "Shares") of common stock allocated as follows: 400,000 restricted
shares issued. in the name of Anthony Freda Jr., and 50,000 warrants with a strike price of 50.15, expiring in three years. The
Shares shall be issued and deemed earned on the date hereof and shall not be refundable regardless of the termination of this Agreement,
and the Shares shall have piggyback registration rights with any registration statement filed on Form S-8 at Company's discretion;
and

 

(b)          the
Company shall reimburse Consultant, or cause it to be reimbursed, for all reasonable out-of-pocket expenses incurred by Consultant
in the performance of the Services hereunder or in furtherance of the business and/or interests of the Company; provided however,
that Consultant shall have previously furnished to the Company an itemized account, reasonably satisfactory to the Company, in
substantiation of such expenditures, and provided that any expenses in excess of 5500 shall require the prior, written consent
of the Company (the "Expenses").

 

Section
3.2Shares and Warrants. Consultant represents and warrants that they are an Accredited Investor, and have completed the
form attached hereto as Exhibit A. Consultant acknowledges and accepts: i) the risk of accepting the Shares and Warrants as
payment for services; and ii) that the Shares and shares acquired through exercise of the Warrants may not be sold without an
effective registration statement or an available exemption from registration and that there is no assurance that such will be
available.

 

SECTION 4

INDEPENDENT CONTRACTOR; REPRESENTATION
AND WARRANTY

 

Section
4.1Status as Independent Contractor. In the performance of the Services, Consultant shall act solely as an
independent contractor, and nothing herein contained or implied will at any time be construed so as to create the
relationship of employer and employee, partnership, principal and agent, or joint venturer as between the Company and
Consultant. Consultant shall have no authority to bind the Company or to make any representations or warranties on behalf of
the Company and shall not represent to any person or entity that she has any other such authority.

 

    	2

    	 

    

 

Section
4.2Taxes. All taxes applicable to this Agreement shall be paid by Consultant, and the Company shall not withhold
or pay any amount for federal, state or municipal income tax, social, security, unemployment or worker's compensation,

 

SECTION 5

GENERAL

 

Section
5.1General Provisions, The following provisions shall apply to this Agreement:

 

Section
5.2Successor and Assigns. This Agreement shall be binding on and inure to the benefit of the Company and Consultant
and their respective successors, assigns, and legal representatives of every kind, character, or nature.

 

Section
5.3 Governing Law. Forum. This Agreement and the rights and obligations of the parties shall be interpreted under and governed
by the laws of the State of New York, without regard to its conflicts of laws principles. Any and all matters of dispute of any
nature whatsoever arising out of or in any way connected with this Agreement or in any way connected with the relationship of
the parties to this Agreement, shall be subject to determination only by the State or Federal courts sitting in Suffolk County,
New York. The parties hereto do hereby consent and submit to the venue and jurisdiction of the State or Federal Courts sitting
in Suffolk County, New York as the sole and exclusive forum for such matters of dispute, and further agree that., in the event
of any action or suit as to any matters of dispute between. the parties, service of any process may be made upon the other party
by mailing a copy of the summons and/or complaint to the other party at the address set forth herein and a party's refusal to
accept any such notice shall be equivalent to service. Without limiting the generality of the foregoing, the Company hereby specifically
waives any claims of inconvenient forum (howsoever denominated) in agreeing to the forum and jurisdiction herein set forth.

 

Section
5.4Entire Agreement.This Agreement constitutes all of the understandings and agreements existing between the parties
hereto concerning the specific subject matter hereof and the rights and obligations created hereunder.

 

Section
5.5Notices. All notices and other communications hereunder shall be in writing and shall be
deemed given upon the earlier to occur of delivery thereof if by hand or upon receipt if sent by mail (registered or
certified mail, postage prepaid, return receipt requested) or on the next business day after deposit if sent by a recognized
overnight delivery service as follows:

 

(a)           
If to Consultant, to:

 

Anthony Freda Jr.

515-6 High St.

Port Jefferson, NY 11777

 

(b)          
If to the Company, to

Viral Genetics, Inc.

1321 Mountain View Circle

Azusa, CA 91702

Attu: Haig Keledjian

 

    	3

    	 

    

 

provided that each of
the parties hereto shall promptly notify the other parties hereto of any change of address, which address shall become such party's
address for the purposes of this Section.

 

Section
5.6 Number and Gender. Whenever appropriate in this Agreement, terms in the singular number shall include the plural number
(and vice versa) and each gender form shall include all others.

 

Section
5.7Attorneys' Fees and Costs. In the event that any legal proceeding concerning the enforcement and interpretation
of the provisions of this Agreement is instituted, the prevailing party in such proceeding shall be entitled to recover its reasonable
attorneys' fees and other expenses related to such proceeding, in addition to any other relief to which it may be entitled.

 

Section
5.8Severability, If any provision or portion of this Agreement is for any reason held to be invalid, illegal, or unenforceable
in any respect, the invalidity, illegality, or unenforccability shall not affect any other provision, and this Agreement shall
be equitably construed as if it did not contain the invalid, illegal, or unenforceable provision. This Agreement shall be construed
equitably in accordance with its terms, without regard to the degree to which Consultant and the Company has participated in drafting
this Agreement.

 

Section
5.9Survival. Any provision hereof which by its terms applies in whole or part after a termination of this Agreement
shall survive such termination and continue in full force and effect.

 

Section
5.10 Cautions. Titles and headings in this Agreement are for reference purposes only and shall in no way limit, define,
or otherwise affect the construction of this Agreement.

 

Section
5.11 No Continuing Waiver. No waiver of any breach of this Agreement shall be effective unless in writing, and no waiver
shall constitute a waiver of any subsequent breach.

 

Section
5.12 Amendment. This Agreement may not be amended, altered, modified, or otherwise changed in any respect except by the
prior written agreement of the parties.

 

Section
5.13 Counterparts. This Agreement may be executed in any number of counterparts, each of which shall be deemed an original
and all of which shall constitute one and the same instrument.

 

Section
5.14 Consultation with Independent Counsel. The parties to this Agreement acknowledge that they have (i) read this Agreement
and consulted with legal counsel of their independent choice concerning the terms hereof, (ii) discussed and reviewed the provisions
of this Agreement with their counsel, and (iii) been fully advised of the legal significance of the provisions of this Agreement.

 

 

    	4

    	 

    

 

IN WITNESS WHEREOF, the undersigned have executed and
delivered this Agreement as of the date first stated above.

 

 

VIRAL GENETICS INC.

 

By: /s/ Haig Keledjian                   

 

 

By: /s/ Anthony Freda Jr.                    

Anthony Freda Jr.

 

 

    	5Exhibit 10.7

 

PURCHASE AGREEMENT

 

THIS AGREEMENT (this “Agreement”)
is made and entered into effective the 1st day of July 2008 between Viral Genetics, Inc., a Delaware corporation, (“Purchase”)
and Michael Capizzano, a California resident, (“Vendor”).

 

RECITALS

 

WHEREAS, Purchaser is desirous
of acquiring and Vendor is desirous of selling forty-nine (49) shares of common stock representing as of the date hereof forty-nine
percent (49%) of the issued and outstanding common stock of White Label Generics, Inc., a California corporation (“White Label”),
(the “Shares”) for the Purchase Price (the “Purchase”) as hereinafter defined.

 

NOW, THEREFORE, in consideration
of the mutual agreements contained herein and other good and valuable consideration, the receipt of which is hereby acknowledged,
the parties agree as follows:

.

ARTICLE I

 

Section 1.1 The Purchase. Upon
execution of this Agreement together with issuance of the Convertible
Debenture, Vendor shall sell, transfer and assign and Purchaser shall purchase the Shares for the sum of $100,000 (the “Purchase
Price”).

 

Section 1.2 Directors and Officers of
White Label. From and after the date hereof, the directors and officers of White Label serving as directors or officers
of White Label immediately prior to the closing shall he the directors and officers following closing.

 

Section 1.3 Restrictions on
Transfer, and Option to Repurchase. Purchaser may not transfer, assign, pledge, encumber or hypothecate the Shares
without the prior written consent of Vendor. For a period of 2 years from the date hereof, Vendor shall have the right to acquire
the Shares back from Purchaser on terms to be negotiated in good faith by Vendor and Purchaser.

 

ARTICLE II

 

Section 2.1 Consideration.
Together with this Agreement, Purchaser shall issue to Vendor the Convertible Note in the form attached hereto as Exhibit
A.

 

ARTICLE III

 

Section 3.1 Representations and
Warranties of Vendor. Vendor hereby represents and warrants that to the best of Vendor's knowledge:

 

(a)White Label is a corporation
duly organized, validly existing and in good standing under the laws of the State of California, and basalt the requisite power
and authority In own, lease and operate its properties and assets and to carry on business as it is now being conducted;

 

(b)White Label is duly qualified
to do business as a foreign person, and is in good standing, in each jurisdiction where such qualification is necessary;

 

(c)White Label is not
in violation of any provisions gins certificate of incorporation or bylaws;

 

(d) White Label has one thousand
five hundred (1,500) shares of common stock authorized of which one hundred (100) are Issued and outstanding, fully-paid and non-assessable;
and

 

    	1

    	 

    

 

(e) Vendor has full authority to enter
into and perform under this Agreement, has obtained all required consents and authorizations and there are no restrictions
on the transfer of the Shares to Purchaser.

 

Section 3.2 Representations and Warranties
of Purchaser. Purchaser hereby represents and warrants that it:

 

(a)is a corporation duly organized, validly
existing and in good standing under the laws of the State of Delaware, and has all the requisite power and authority to own, lease
and operate its properties and assigns and to carry on business as it is now being conducted.

 

(b)is duly qualified to
do business as a foreign person, and is in good standing, in each jurisdiction where: the character of it properties or the nature
of its activities make such qualification necessary;

 

(c)is not in violation of any provisions
of its certificate of incorporation or bylaws; and

 

(d)has full power and authority to execute
and perform under this Agreement.

 

Section 3.3 Securities Act and State
Securities Laws. The parties wilt take such further action deemed necessary to reasonably rely On exemptions
for sales, transfers or issuances of securities under and comply with applicable law with respect to this Agreement. Vendor has
received and read all reports Filed by Purchaser with the Securities Exchange Commission on forms 10-KSB, 10-QSB, 8-K and all other
public disclosures made by Purchaser.

 

ARTICLE IV

 

MISCELLANEOUS

 

Section 4.1.No Waivers.
No failure or delay by any party hereto exercising any right, power or privilege hereunder shall operate as a waiver thereof
nor shall any single or partial exercise thereof preclude any other further exercise thereof or the exercise of any other
right power or privilege. The rights and remedies herein provided shall be cumulative and not exclusive of any rights or remedies
provided by law

 

Section 4.2 Assignment.
Except with respect to Vendor's rights to assign the Convertible Note as defined therein, neither this Agreement, nor any
right, interest or obligation hereunder, shall be assigned to any of the parties hereto without the prior written consent of the
other parties. This Agreement shall be binding upon and inure to the benefit of the parties hereto and their respective successors
and assigns.

 

Section 4.3 Governing Law.
This Agreement shall be governed by the laws of the State of California.

 

Section 4.4 Counterparts.
This Agreement may be executed in one or more counterparts, each of which shall he deemed an original but all of which together
shall constitute one and the same instrument.

 

Section 4.5 Entire Agreement.
This Agreement supersedes all prior agreements and understandings, written or oral, among the parties with respect to the
subject matter hereof.

 

    	2

    	 

    

 

 

IN WITNESS WHEREOF, the undersigned intending to be legally bound hereby, have duly executed this
Agreement as of the date first stated above.

 

	 	Michael Capizzano

                            

                           By: /s/ Michael Capizzano

	 	 
	 	 
	 	Viral Genetics, Inc.
	 	 
	 	By: Haig Keledjian
	 	Name: Haig Keledjian
	 	Title: President and CEO

 

 

 

 

 

 

    	3

    	 

    

 

EXHIBIT A

 

 

THIS DEBENTURE AND THE SECURITIES
ISSUABLE UPON CONVERSION OF THIS DEBENTURE HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE
“SECURITIES ACT”), OR ANY STATE SECURITIES LAW, AND MAY NOT  BE OFFERED FOR SALE OR SOLD UNLESS A REGISTRATION
STATEMENT UNDER SUCH ACT ANT) APPLICABLE STATE SECURITIES LAWS SHALL BE EFFECTIVE WITH RESPECT THERETO OR AN EXEMPTION FROM
REGISTRATION UNDER THE SECURITIES ACT AND APPLICABLE STATE SECURITIES LAWS IS AVAILABLE IN CONNECTION WITH SUCH OFFER OR
SALE.

 

VIRAL GENETICS, INC.

10% CONVERTIBLE DEBENTURE

 

	San Marino, California	$100,000

 

Issue Date; July 1,2008

 

FOR VALUE RECEIVED, VIRAL GENETICS, INC., a
Delaware corporation (the “Company”), hereby promises to pay to the order of Michael Capizzanio or his
permitted successors or assigns (the “Holder”) the sum of one hundred thousand dollars ($100.00) in same
day funds of the lawful currency of the United States of America, on or before July 1, 2011 (the “Maturity Date”).
The Holder may convert amounts of this Debenture into shares (“Conversion Shares”) of the Company's
common stock, par value $0.0001 per share (the “Common Stock”), on the terms and subject to the
conditions set forth herein.

 

The Company has issued this Debenture pursuant
to a Purchase Agreement, dated as of the date hereof (the "Purchase Agreement”).

 

1.       PAYMENT.

 

(a)Principal Payment. The
Company shall pay to the Holder, in cash on or before the Maturity Date, the original principal amount of this Debenture
(plus unpaid accrued interest thereon); provided, that if the Maturity Date is not a business day, such payment
shall be made on the next succeeding business day. The Principal Payment that is due in cash and which is not paid on the Maturity
Date shill bear interest until paid at the Default Interest Rate of eighteen percent (18%).

 

(b)Interest Accrual.
This Debenture shall bear interest on the unpaid principal amount hereof ("Interest") at
the Applicable Interest Rate of ten percent (10%). The Company shall pay in cash accrued and unpaid Interest on the Maturity Date
and on any date on which the entire principal amount of this Debenture is paid in full (each being referred to herein as an
“Interest Payment Date").

 

(c)Prepayment. Company may elect
to prepay this note at any time by giving 30 calendar days written advance notice to Holder, during which lime -Holder
shall have the right in exercise all rights herein including, without limitation, conversion rights as specified in Section 2.

 

2.       CONVERSION.

 

(a)Right to Convert. The Holder shall have the right
to convert, at any time and from time to time after the Issue Date, all or any part of the outstanding and unpaid principal
and interest amount of
this Debenture into such number of fully paid and non-assessable Conversion Shares as is determined in accordance with the terms
hereof (a "Conversion").

 

    	4

    	 

    

 

(b)Conversion Notice. In order to convert principal of
this Debenture, the Holder shall send by facsimile transmission, at any time prior to 5:00 p.m., Pacific Time, on the business
day on which the Holder wishes to effect such Conversion (the “Conversion Date”), a properly completed notice
of conversion to the Company, in the form set forth on Annex I hereto, stating the amount of principal (and, if the Holder
so elects, interest) to be converted and a calculation of the number of shares of Common Stock issuable upon such Conversion
(a "Conversion Notice"). The Conversion Notice shall also state the name or names (if not the Holder) it; which
the shares of Common Stock that are issuable on such Conversion shall be issued. The Holder shall not be required to physically
surrender this Debenture to the Company in order to effect a Conversion, unless such Conversion would represent payment in full
of the Debenture. The Company shall maintain a record showing, at any given time, the unpaid principal amount of this Debenture
arid the date of each Conversion or other payment of principal hereof.

 

(c)Number of Conversion Shares; Conversion Price. The
number of Conversion Shares to be delivered by the Company pursuant to a Conversion shall be equal to the amount specified in the
Conversion Notice divided by the Conversion Price. The Conversion Price is $0.0133 subject to adjustment as provided for in Section
3.

 

(d)Delivery of
Common Stock Upon Conversion. Upon receipt of a Conversion Notice, the Company shall,
no later than the close of business on the fifth (5th) Business day following the Conversion Date set
forth in such Conversion Notice (the “Delivery Date”), issue and deliver or cause to be delivered to the Holder
the number of Conversion Shares determined pursuant to paragraph 3(c) above. The Company shall effect delivery of Conversion Shares
to the Holder no later than the close of business on such Delivery Date by delivering to the Holder or its nominee physical certificates
representing such Conversion Shares. If any Conversion would create a fractional Conversion Share, such fractional Conversion
Share shall be disregarded and the number of Conversion Shares issuable upon such Conversion, in the aggregate, shall be the
nearest whole number of Conversion Shares.

 

3.       ADJUSTMENTS
TO CONVERSION PRICE.

 

(a)Stock Dividends
and Stock splits.
If the Company, at any time while this Debenture is outstanding: (A) pays a stock dividend or otherwise makes a
distribution or distributions on shares of its Common Stock or any other equity or equity equivalent securities payable
in shares of Common Stock (which, for avoidance of doubt, shall not include any shares of Common Stock issued by the Company
pursuant to this Debenture, including as interest thereon), (B) subdivides outstanding shares of Common Stock into a larger number
of shares, (C) combines (including by way of reverse stock split) outstanding shares of Common Stock into a smaller number
of shares, or (D) issues by reclassification of shares of the Common Stock any shares of capital stock of the Company,
then the Conversion Price shall be multiplied by a fraction of which the numerator shall be the number of shares of
Common Stock (excluding treasury shares, if any) outstanding immediately before such event and of which the denominator shall
be the number of shares Common Stock outstanding immediately after
such event. Any adjustment made pursuant to this Section shall become effective immediately after the record date for the determination
of stockholders entitled to receive such dividend or distribution and shall become effective immediately after the effective
date in the class of a subdivision, combination or re-classification.

 

    	5

    	 

    

 

(b)Fundamental
Transaction. If, at any time while this Debenture is outstanding, (A) the Company effects any merger or consolidation
of the Company with or into another entity, (B) the Company effects any sale of all or substantially all of its assets
in one or a series of related transactions, (C) any tender offer or exchange offer (whether by the Company or another person)
is completed pursuant to which holders of Common Stock are permitted to tender or exchange their shares for other securities,
cash or property, or (D) the Company effects any reclassification of the Common Stock or any compulsory share exchange pursuant
to which the Common Stock is effectively converted into or exchanged for other securities, cash or property (in any such case,
a “Fundamental Transaction"), then upon any subsequent conversion of this Debenture, the Holder shall have the
right to receive, for each Conversion Share that would have been issuable upon such conversion immediately prior to the occurrence
of such Fundamental Transaction, the same kind and amount of securities, cash or property as it would have been entitled to receive
upon the occurrence of such Fundamental Transaction if it had been, immediately prior to such Fundamental Transaction, the holder
of one share of Common Stock (the “Alternate Consideration”). For purposes of any such conversion, the determination
of the Conversion Price shall be appropriately adjusted to apply to such Alternate Consideration based on the amount of
Alternate Consideration issuable in respect of one share of Common Stock in such Fundamental Transaction, and the Company shall
apportion the Conversion Price among the Alternate Consideration in a reasonable manner reflecting the relative value of any different
components of the Alternate Consideration. If holders of Common Stock are given any choice as to the securities, cash or property
to be received in a Fundamental Transaction, then the Holder shall be given the same choice as in the Alternate
Consideration it receives upon any conversion of this Debenture following such Fundamental Transaction. To the extent necessary
to effectuate the foregoing provisions, any successor to the Company or surviving entity in such Fundamental Transaction shall
issue to the Holder a new debenture consistent with the foregoing provisions and evidencing the Holder’s right to convert
such debenture into Alternate Consideration. The terms of any agreement pursuant to which a Fundamental Transaction is effected
shall include terms requiring any such successor or surviving entity to comply with the provisions of this paragraph (b) and insuring
that this Debenture (or city such replacement security) will be similarly adjusted upon any subsequent transaction analogous to
a Fundamental Transaction.

 

(c)Adjustment
Upon Dilutive Issuance. If at any time after the Issue Date and prior to the Maturity Date, the Company issues or sells any
shares of Common Stock for no consideration or for a consideration per share less than the Conversion Price on the date of such
issuance or sale (or deemed issuance or sale) (a “Dilutive Issuance”), then effective immediately upon the
Dilutive Issuance, the conversion price shall be adjusted sect, that affective immediately upon such Dilutive Issuance, the Conversion
Price shall be adjusted so as to equal the consideration received or receivable by the Corporation (on a per share basis) for
the additional shares of Common Stock so issued, sold or deemed issued or sold in such Dilutive Issuance.

 

4.       MISCELLANEOUS.

 

(a)Failure to Exercise Rights not Waiver. No failure
or delay on the part of the Holder in the exercise of any power, right or privilege hereunder shall operate as a waiver thereof,
nor shall any single or partial exercise of any such power, right or privilege preclude any other or further exercise thereof.
All rights and remedies of the Holder hereunder arc cumulative and not exclusive of any rights or remedies otherwise available.

 

(b)Notices. Any notice, demand or request required or
permitted to be given by the Company or the Holder pursuant to the terms of this Debenture shall he in writing and shall be deemed
delivered (1) when delivered personally or by verifiable facsimile transmission, unless such delivery is made on a day that is
not a business day, in which case such delivery will be deemed to be made on the next succeeding business day and (ii) on the next
business day after timely delivery to an overnight courier, addressed as follows:

 

If to the Company:

 

Viral Genetics, Inc.

 

    	6

    	 

    

 

2290 Huntington Drive, #100

San Marino, CA 91108

Attn: Chief Executive Officer

 

Tel:   626-334-5310

 

Fax:   626-334-5324

 

 

If to the Holder:

 

Michael Capizzano

 

178.1 College View Place

 

Los Angeles, CA 90041

 

(c)Amendments,
No amendment, modification or other chew to, or waiver of any provision if, this Debenture may be made unless such amendment,
modification or change is set forth in writing and is signed by the Company and the Holder.

 

(d)Transfer of Debenture. The Holder may sell, transfer
or otherwise dispose of all or any part of this Debenture (including without limitation pursuant to a pledge) to any person or
entity as long as such sale, transfer or disposition is the subject
of effective registration statement under the Securities Act and applicable state securities laws, or is exempt from registration
thereunder. From and after the date or any such sale, transfer or disposition, the transferee hereof shall be deemed to be the
holder of a Debenture in the principal amount acquired by such transferee, and the Company shall, as promptly as practicable, issue
and deliver to such transferee a new Debenture identical in all respects to this Debenture, in the name of such transferee. The
Company shall be entitled to treat the original Holder as the holder of this entire Debenture unless and until it receives written
notice of the sale, transfer or disposition hereof.

 

(e)Lost or Stolen Debenture. Upon receipt by the Company
of evidence of the loss, theft, destruction or mutilation of this Debenture, and (in the case of loss, theft or destruction) of
indemnity or security reasonably satisfactory to the Company, and upon surrender and cancellation of the Debenture, if mutilated,
the Company shall execute and deliver to the Holder a new Debenture identical in all respects to this Debenture.

 

(f)Governing Law.
This Debenture shall be governed by the laws of the Stare of California.

 

(g)Successors and Assigns. The terms
and conditions of this Debenture shall inure to the benefit of and be binding upon the respective successors (whether by merger
or otherwise) and permitted assigns of the Company and the Holder. The Company may not assign its rights or obligations under this
Debenture except as specifically required or permitted pursuant to the terms hereof.

 

(h)Usury.
This Debenture is subject to the express condition that at no time shall the Company be obligated or required to pay interest
hereunder at a rate which could subject the Holder to either civil or criminal liability as a result of being in excess of the
maximum interest rate which the Company is permitted by applicable law to contract or agree to pay, if by the terms of this Debenture,
the Company is at any time required or obligated to pay interest hereunder at a rate in excess of such maximum rate, the rate
of interest under this Debenture shall be deemed to be immediately reduced to such maximum rate and the interest payable shall
he computed at such maximum rate and all prior interest payments in excess of such maximum rate shall be applied and shall be
deemed to have been payments in reduction of the principal balance of this Debenture.

 

 

    	7

    	 

    

 

IN WITNESS WHEREOF, the Company has caused this
Debenture to be signed in its name by its duly authorized officer on the date first above written.

 

VIRAL GENETICS,INC.

 

By: /s/ Haig Keledjian

       Name: Haig Keledjian

       Title, CEO, President

 

 

 

 

 

 

 

 

 

 

 

    	8

    	 

    

 

ANNEX I

 

NOTICE OF CONVERSION

 

The undersigned hereby elects to convert principal
or and/or interest accrued on the Convertible Debenture (the "Debenture”)) issue by VIRAL GENETICS, Inc. (the “Corporation”)
into shares of common stock ("Common Stock”) of the Company according to the terms and conditions of the Debenture.
Capitalized terms used herein and not otherwise defined shall have the respective meanings set forth in the Debenture.

 

 

	 	Date of Conversion:	 
	 	 	 
	 	Principal Amount of Debenture to be Converted:	 
	 	 	 
	 	Amount of Interest to be Converted:	 
	 	 	 
	 	Number of Shares of Common Stock to be issued:	 
	 	 	 
	 	Name of Holder:	 
	 	 	 
	 	Address:	 
	 	 	 
	 	 	 
	 	 	 
	 	Signature	 
	 	 	Name:
	 	 	Title:

 

 

 

    	9

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00232-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00232-of-00352.parquet"}]]